MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)

Consensus Ratings for Infinity Pharmaceuticals (NASDAQ:INFI) (?)
Ratings Breakdown: 3 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $18.13 (105.50% upside)

Analysts' Ratings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Show:
DateFirmActionRatingPrice TargetActions
8/7/2015RBC CapitalReiterated RatingOutperform$18.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Jefferies GroupSet Price TargetBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2015NomuraReiterated RatingNeutral -> Buy$17.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2015RBC CapitalReiterated RatingOutperform$20.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Deutsche BankInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/5/2015Morgan StanleyDowngradeOverweight -> Equal Weight$19.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Credit SuisseUpgradeNeutral -> Outperform$20.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/20/2014Stifel NicolausInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/5/2014NomuraBoost Price Target$12.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Jefferies GroupBoost Price TargetBuy$13.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014JMP SecuritiesUpgradeMarket Perform -> Outperform$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/3/2014Roth CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/3/2014WedbushUpgradeUnderperform -> Neutral$9.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2014William BlairUpgradeOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2014Morgan StanleyInitiated CoverageOverweight$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2014WedbushLower Price Target$10.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014Stifel NicolausReiterated RatingBuy$25.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014JPMorgan Chase & Co.Reiterated RatingOverweight$24.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014Jefferies GroupUpgradeHold -> Buy$15.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014NomuraLower Price Target$17.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014WedbushInitiated CoverageUnderperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2014NomuraBoost Price Target$14.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2014Jefferies GroupBoost Price Target$13.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2014NomuraInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/12/2013Credit SuisseDowngradeOutperform -> Neutral$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/23/2013William BlairInitiated CoverageMarket Perform$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/18/2013Goldman SachsBoost Price Target$20.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 9/1/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha